![](https://lifescicommunications.com/wp-content/uploads/2018/04/SCRIP--300x139.png)
Samumed CMO Hopes To Reach Drug Approvals Via The Wnt Pathway
The clinical-stage biotech has diverse pipeline generated by its Wnt signalling pathway technology platform, and aims to get its first drug to market in 2020.
![](https://lifescicommunications.com/wp-content/uploads/2018/04/labiotech_eu-RVB-big-300x60.png)
“This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukemia“
Celyad has reported clinical results showing the first time a patient has fully recovered from acute myeloid leukemia thanks to a CAR-T therapy, and without the need for chemotherapy preconditioning.
![](https://lifescicommunications.com/wp-content/uploads/2018/04/bloomberg-2-300x56.png)
Bloomberg Markets: ICO Compliance, Drug Development
Amit Munshi President/CEO Arena Pharmaceuticals Inc Discussing drug development in ulcerative colitis space.
![](https://lifescicommunications.com/wp-content/uploads/2018/04/2000px-CNBC_logo.svg-300x240.png)
Arena CEO: We have two great assets and are trying to build a company around that
Looking at the performance of Arena Pharmaceuticals with CEO Amit Munshi and CNBC’s Meg Tirrell.
![](https://lifescicommunications.com/wp-content/uploads/2018/04/a3912338358eaf54c75fd812c3f44f3f-300x57.jpg)
Orchard Gains GSK’S Rare Disease Gene Therapy Portfolio
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will divest its rare disease gene therapy portfolio, including Strimvelis, to Orchard Therapeutics Ltd. (London, U.K.).
![](https://lifescicommunications.com/wp-content/uploads/2018/04/Reuters-Logo-1-300x98.png)
UK gene therapy firm Orchard plans stock offer after GSK deal
Britain’s Orchard Therapeutics, which has already raised more than $140 million to fund its work in gene therapy, plans another private sale of shares following its acquisition of a portfolio of GlaxoSmithKline…
![](https://lifescicommunications.com/wp-content/uploads/2018/04/SCRIP--300x139.png)
OSE Immunotherapeutics Adds Boehringer Ingelheim To Its Pharma Partnering List
Collaborating with the German family-controlled drug maker on OSE’s novel checkpoint inhibitor aligns with French firm’s strategy of partnering its portfolio candidates.
![](https://lifescicommunications.com/wp-content/uploads/2018/04/lifescienceleader-300x83.png)
Reata Pharmaceuticals: Return & Reach Beyond
The Enterprisers: Life Science Leadership In Action. What good can come of setback? What is the value, if any, in so-called failure? Must a “failed” clinical trial wind up in the great waste bin of misbegotten science?